Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

Biological and clinical implications of endocan in gastric cancer

Authors: Wenyan Zhao, Ming Sun, Shuqiang Li, Yong Wang, Jingang Liu

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

Endocan overexpression has been reported to be associated with poor prognosis in various cancer types such as breast cancer, kidney cancer, and lung cancer. However, the biological and prognostic significance of endocan in gastric cancer remains unknown. Here, we investigated the expression status of endocan in gastric cancer. Endocan expression status was determined in 255 gastric cancer specimens by immunohistochemical staining. The association of endocan protein with clinicopathological parameters and prognosis was subsequently determined. The oncogenic role of endocan in gastric cancer was examined using a small interfering RNA (siRNA) approach. Spearman regression correlation analysis showed that endocan expression was associated with the pathological tumor stage. In Cox regression analysis, endocan expression was found to be an independent prognostic factor for survival. Endocan promoted gastric cancer cell proliferation. Our findings indicate that endocan is a potential target for therapeutic intervention in gastric cancer.
Literature
1.
Corso G, Seruca R, Roviello F. Gastric cancer carcinogenesis and tumor progression. Ann Ital Chir. 2012;83(3):172–6.PubMed
2.
Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37:417–25.CrossRefPubMed
3.
Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.PubMed
4.
Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006;72:136–45.CrossRefPubMed
5.
Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res. 2003;63:6084–9.PubMed
6.
Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009;69:836–44.CrossRefPubMed
7.
Cornelius A, Cortet-Rudelli C, Assaker R, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757–64.CrossRefPubMed
8.
Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12:4575–82.CrossRefPubMed
9.
Liu N, Zhang LH, Du H, et al. Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol. 2010;17:2628–39.CrossRefPubMed
10.
Ji NY, Kim YH, Jang YJ, et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci. 2010;101:2248–53.CrossRefPubMed
11.
Kim JH, Park MY, Kim CN, et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1 alpha in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep. 2012;28:1701–8.PubMed
12.
Roudnicky F, Poyet C, Wild P, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013;73:1097–106.CrossRefPubMed
13.
El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. 2013;288:1371–6.CrossRefPubMed
14.
Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009;54:389–94.CrossRefPubMed
15.
Chen LY, Liu X, Wang SL, Qin CY. Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res. 2010;38:498–510.CrossRefPubMed
16.
Kang YH, Ji NY, Lee CI, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids. 2011;40:1003–13.CrossRefPubMed
17.
Maurage CA, Adam E, Minéo JF, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009;68:633–41.CrossRefPubMed
18.
Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 2008;112:2318–26.PubMedCentralCrossRefPubMed
19.
Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res. 2007;313:1285–94.CrossRefPubMed
20.
Leroy X, Aubert S, Zini L, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56:180–7.CrossRefPubMed
21.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
22.
Xiong JX, Wu Q, Zhou Q, Wu ZS, Gui SY, Wang Y. Expression and relation between endothelial cell specific molecule-1 mRNA and protein in renal cell carcinoma. J Clin Exp Pathol. 2004;20:187–9.
23.
Perey L, Benhattar J, Peters R, Jaunin P, Leyvraz S. High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR. Br J Cancer. 2001;85:1713–21.PubMedCentralCrossRefPubMed
24.
van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef
25.
Zuo L, Zhang SM, Hu RL, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol. 2008;14:4562–8.PubMedCentralCrossRefPubMed
Metadata
Title
Biological and clinical implications of endocan in gastric cancer
Authors
Wenyan Zhao
Ming Sun
Shuqiang Li
Yong Wang
Jingang Liu
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2287-0

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue

Research Article

Gingerol-derivatives: emerging new therapy against human drug-resistant MCF-7

Research Article

BAT3 rs1052486 and rs3117582 polymorphisms are associated with lung cancer risk: a meta-analysis

Research Article

Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis

Research Article

Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients

Research Article

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Research Article

Effects of leptin and leptin receptor gene polymorphisms on lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits